Efficacy of Ceftibut3en + VNRX-5236 in the murine UTI model

StatusFinished
Effective start/end date1/06/1831/01/19

Funding

  • VenatoRx Pharmaceuticals, Inc.: $101,627.94

Keywords

  • Other